The United Kingdom and the United States have signed a important bilateral deal that will guarantee zero levies on British medicine products entering the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase funding on drugs through the public health system. This commitment guarantees that tariffs on these vital exports will stay at zero for a timeframe of the next three years.
This development is in response to recent statements to dramatically increase tariffs on patented drug products, with figures floated up to 100%.
"This deal with the Britain strengthens the international landscape for innovative medicines and introduces long-overdue equity to American-British drug exports," a release said.
Commercial Impact
Drugs constitute one of the UK's largest export categories to the United States, which is clearly the primary destination for major UK drugmakers.
Export figures show that in the one-year period to the end of September, the UK sold pharmaceutical products valued at billions to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This deal secures jobs, stimulates investment and sets the stage for the UK to become a global hub for life sciences," a government official commented.
Specific UK Commitments
The pact includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. In the past, refunds topped twenty percent.
Recent Tensions
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by claims that US customers were paying several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial investments have been directed toward American operations.
A senior figure stated that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the past decade.
